Literature DB >> 12631452

Gallstone pancreatitis: when is endoscopic retrograde cholangiopancreatography truly necessary?

Matthias Kraft1, Markus M Lerch.   

Abstract

Acute pancreatitis is an inflammation of the pancreas that can, in a minority of patients, lead to local complications, multiorgan failure, and death. Gallstones are the most common cause of acute pancreatitis in Western countries. The majority of patients with acute gallstone pancreatitis have mild disease and recover within 3 to 5 days with bed rest and intravenous fluid replacement. In up to 20% of patients, severe pancreatitis develops and can involve pancreatic tissue necrosis and multiorgan failure. Recent advances in the care of patients with gallstone-induced pancreatitis include better severity stratification on hospital admission, more aggressive fluid resuscitation in the early disease course, early use of antibiotics in patients with pancreatic necrosis, a shift from parenteral to enteral feeding regimens, a better defined and less aggressive approach to pancreatic surgery, and the possibility to remove impacted gallstones endoscopically. Urgent endoscopic retrograde cholangiopancreatography and sphincterotomy are recommended in patients with signs of cholangitis or jaundice, ultrasound evidence of dilated common bile duct, or evidence of severe disease.

Entities:  

Mesh:

Year:  2003        PMID: 12631452     DOI: 10.1007/s11894-003-0081-z

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  45 in total

1.  Where do ERCP, endoscopic ultrasound, magnetic resonance cholangiopancreatography, and intraoperative cholangiography fit in the management of acute biliary pancreatitis? A decision analysis model.

Authors:  M R Arguedas; A W Dupont; C M Wilcox
Journal:  Am J Gastroenterol       Date:  2001-10       Impact factor: 10.864

2.  Hemoconcentration is an early marker for organ failure and necrotizing pancreatitis.

Authors:  A Brown; J Orav; P A Banks
Journal:  Pancreas       Date:  2000-05       Impact factor: 3.327

3.  Hereditary pancreatitis caused by a novel PRSS1 mutation (Arg-122 --> Cys) that alters autoactivation and autodegradation of cationic trypsinogen.

Authors:  Peter Simon; F Ulrich Weiss; Miklos Sahin-Toth; Marina Parry; Oliver Nayler; Berthold Lenfers; Jurgen Schnekenburger; Julia Mayerle; Wolfram Domschke; Markus M Lerch
Journal:  J Biol Chem       Date:  2001-11-21       Impact factor: 5.157

4.  Successes, failures, early complications and their management following endoscopic sphincterotomy: results in 394 consecutive patients from a single centre.

Authors:  T Leese; J P Neoptolemos; D L Carr-Locke
Journal:  Br J Surg       Date:  1985-03       Impact factor: 6.939

5.  Value of endoscopic retrograde cholangiopancreatography in determining the cause but not course of acute pancreatitis.

Authors:  J Schölmerich; M Lausen; L Lay; R Salm; K Rückauer; V Gross; M Roth; H G Leser; E H Farthmann
Journal:  Endoscopy       Date:  1992-05       Impact factor: 10.093

6.  Sphincter of Oddi dysfunction: pancreaticobiliary sphincterotomy with pancreatic stent placement has a lower rate of pancreatitis than biliary sphincterotomy alone.

Authors:  E L Fogel; D Eversman; P Jamidar; S Sherman; G A Lehman
Journal:  Endoscopy       Date:  2002-04       Impact factor: 10.093

7.  Management of gallstone pancreatitis: effects of deviation from clinical guidelines.

Authors:  K Sargen; A N Kingsnorth
Journal:  JOP       Date:  2001-09

8.  Acute pancreatitis: value of CT in establishing prognosis.

Authors:  E J Balthazar; D L Robinson; A J Megibow; J H Ranson
Journal:  Radiology       Date:  1990-02       Impact factor: 11.105

9.  Sphincter stenosis and gallstone migration through the biliary tract.

Authors:  C A Hernández; M M Lerch
Journal:  Lancet       Date:  1993-05-29       Impact factor: 79.321

10.  Biliary pancreatitis: clinical presentation and surgical management.

Authors:  G J Frei; V T Frei; R C Thirlby; R N McClelland
Journal:  Am J Surg       Date:  1986-01       Impact factor: 2.565

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.